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Abstract
Oxidative stress is believed to be a major driver of inflammation in smoking asthmatics. The
U-BIOPRED project recruited a cohort of Severe Asthma smokers/ex-smokers (SAs/ex)
and non-smokers (SAn) with extensive clinical and biomarker information enabling charac-
terization of these subjects. We investigated oxidative stress in severe asthma subjects by
analysing urinary 8-iso-PGF2α and the mRNA-expression of the main pro-oxidant (NOX2;
NOSs) and anti-oxidant (SODs; CAT; GPX1) enzymes in the airways of SAs/ex and SAn.
All the severe asthma U-BIOPRED subjects were further divided into current smokers with
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severe asthma (CSA), ex-smokers with severe asthma (ESA) and non-smokers with severe
asthma (NSA) to deepen the effect of active smoking. Clinical data, urine and sputum were
obtained from severe asthma subjects. A bronchoscopy to obtain bronchial biopsy and
brushing was performed in a subset of subjects. The main clinical data were analysed for
each subset of subjects (urine-8-iso-PGF2α; IS-transcriptomics; BB-transcriptomics; BBr-
transcriptomics). Urinary 8-iso-PGF2α was quantified using mass spectrometry. Sputum,
bronchial biopsy and bronchial brushing were processed for mRNA expression microarray
analysis. Urinary 8-iso-PGF2α was increased in SAs/ex, median (IQR) = 31.7 (24.5–44.7)
ng/mmol creatinine, compared to SAn, median (IQR) = 26.6 (19.6–36.6) ng/mmol creatinine
(p< 0.001), and in CSA, median (IQR) = 34.25 (24.4–47.7), vs. ESA, median (IQR) = 29.4
(22.3–40.5), and NSA, median (IQR) = 26.5 (19.6–16.6) ng/mmol creatinine (p = 0.004).
Sputum mRNA expression of NOX2 was increased in SAs/ex compared to SAn (probe sets
203922_PM_s_at fold-change = 1.05 p = 0.006; 203923_PM_s_at fold-change = 1.06, p =
0.003; 233538_PM_s_at fold-change = 1.06, p = 0.014). The mRNA expression of antioxi-
dant enzymes were similar between the two severe asthma cohorts in all airway samples.
NOS2 mRNA expression was decreased in bronchial brushing of SAs/ex compared to SAn
(fold-change = -1.10; p = 0.029). NOS2 mRNA expression in bronchial brushing correlated
with FeNO (Kendal’s Tau = 0.535; p< 0.001). From clinical and inflammatory analysis,
FeNO was lower in CSA than in ESA in all the analysed subject subsets (p< 0.01) indicating
an effect of active smoking. Results about FeNO suggest its clinical limitation, as inflamma-
tion biomarker, in severe asthma active smokers. These data provide evidence of greater
systemic oxidative stress in severe asthma smokers as reflected by a significant changes of
NOX2 mRNA expression in the airways, together with elevated urinary 8-iso-PGF2α in the
smokers/ex-smokers group.
Trial registration ClinicalTrials.gov—Identifier: NCT01976767
Introduction
Asthma is a heterogeneous inflammatory syndrome of the airways characterized by several
clinical and molecular phenotypes [1–3]. In severe asthma (SA), genetic, immunologic and
environmental factors interact contributing to airway chronic inflammation [4]. Cigarette
smoke is a key factor implicated in modulation of asthma. Data on asthmatic smokers suggest
marked impairment in asthma control, accelerated decline in lung function, increased airflow
obstruction and increase in disease severity [5].
Human airways are normally exposed to oxidative products present in environmental pol-
lutants. But, the inflammatory state in the airways of asthmatic patients may also promote
oxidative stress with increased levels of reactive oxygen species (ROS) and reactive nitrogen
species (RNS)[6], which may further contribute to maintenance and progression of the inflam-
matory response and disease exacerbation [7]. Activated inflammatory cells produce anion
superoxide (O2•-) through the NADPH oxidase pathway. The O2•- is neutralized by superox-
ide dismutase enzymes (SODs), catalase (CAT) and glutathione peroxidase (GPX) activity [8].
Furthermore, nitric oxide synthase (NOS) enzymes generate nitric oxide (NO)[9], another
common free radical, that in the presence of ROS rapidly forms RNS [8]. An excess of ROS
and RNS has been shown to lead to membrane lipids peroxidation, nicotinamide nucleotides
Oxidative stress in Severe Asthma U-BIOPRED cohorts
PLOS ONE | https://doi.org/10.1371/journal.pone.0203874 September 21, 2018 2 / 16
companies’ in kind contribution (www.imi.europa.
eu). We would also like to acknowledge help from
the IMI funded eTRIKS project (EU Grant Code
No.115446 to R.E.). Funding information for this
article has been deposited with FundRef. The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript. Acclarogen Ltd., Janssen
Research & Development, LLC., GSK, Astra Zeneca
R&D and Areteva R&D provided support in the
form of salaries for authors ATB, MJL, ARS, AND
JC but did not have any additional role in the study
design, data collection and analysis, decision to
publish, or preparation of the manuscript. The
specific roles of these authors are articulated in the
‘author contributions’ section.
Competing interests: M. Caruso, R. Emma, A.T.
Bansal, C.E. Wheelock, M.J. Loza, L. Fabbella, T.
Sandstrom, F. Singer, A.R. Sousa, D.E. Shaw, R.
Lutter, S.J. Fowler, I. Horvath, I. Pandis, P.
Montuschi declare non conflict of interest. J.
Kolmert, B. De Meulder, D. Lefaudeux, C. Auffray,
P.J. Sterk, N. Krug, M. Sanak, J. Corfield declare
grants from IMI (Innovative Medicine Initiatives)
during the conduct of the study. S.E. Dahlen
declares financial supporting by Swedish Research
Academic Foundations, RSPS Incentive, AZ, Teva
and GSK consultancies. B. Dahlen declares
consultancies for TEVA. P. Chanez reports grants
and personal fees from Almirall, BI, Centocor, GSK,
MSD, AstraZeneca, Novartis, Teva, Chiesi,
Schering Plough, outside the submitted work. P.S.
Bakke reports personal fees from GlaxoSmithKline,
Boehringer-Ingelheim, AstraZeneca, Orionpharma,
Mundipharma, outside the submitted work. R.
Djukanovic reports receiving fees for lectures at
symposia organised by Novartis and TEVA and
consultation for these two companies as member
of advisory boards. He is a co-founder and current
consultant, and has shares in Synairgen, a
University of Southampton spin out company. P.H.
Howarth reports fees from GSK, outside the
submitted work. L. Fleming reports personal fees
and other from Vectura, Novartis, Boehringer
ingelheim, outside the submitted work. I. Adcock
reports grants from EU-IMI, during the conduct of
the study; grants from MRC, BHF, Dunhill Medical
Trust, personal fees from Chiesi, GSK, Boehringer
Ingelheim, outside the submitted work. K.F. Chung
reports personal fees from Advisory Board
membership, grants for research, and personal
fees from payments for lectures, outside the
submitted work. ATB is employed by Acclarogen
Ltd., MJL by Janssen Research & Development,
LLC., ARS by GSK and JC by Astra Zeneca R&D
and Areteva R&D. There are no patents, products
in development or marketed products to declare.
depletion, enhanced intracellular Ca2+, cytoskeleton breakage and DNA damage [8,10]. The
peroxidative breakdown of membrane fatty acids by ROS leads to F2-Isoprostanes production.
8-Isoprostaglandin F2α (8-iso-PGF2α) is therefore considered a useful marker of oxidative
stress [11].
Tobacco smoke is a major exogenous source of oxidative stress, contributing to subsistence
and progression of the inflammatory response and disease chronicity in asthma. Many oxidant
compounds are present in cigarette smoke, which may induce direct and/or indirect oxidative
damage [12]. Very little is known about the role of oxidative stress in SA and even less about
the combined impact with cigarette smoking. We tested the hypothesis that oxidative stress
and inflammatory biomarkes differs in SA subjects with and without a significant smoking his-
tory, as well as in SA current-, ex- and non-smokers.
We therefore investigated the level of the lipid peroxidation marker 8-iso-PGF2α in the
urine and the mRNA expression profile of key pro-oxidant (NADPH oxidase 2, NOX2; induc-
ible NOS, NOS2; constitutive NOSs, NOS1 and NOS3) and anti-oxidant (superoxide dismu-
tases, SOD1, -2 and -3; catalase, CAT; and glutathione peroxidase 1, GPX1) enzymes in the
airways, in particular in bronchial biopsy (BB), bronchial brushing (BBr) and induced sputum
(IS) samples.
Materials and methods
Materials and methods section is fully described in the online S1 File. Material and Methods.
Subjects
The Severe Asthma U-BIOPRED participants were enrolled in two groups [13]:
• Severe non-smoking asthma (SAn): subjects in this group refrained from smoking for at least
12 months prior to the study, with a less than five pack-years smoking history. They had
uncontrolled symptoms as defined according to GINA guidelines [14] and/or frequent exac-
erbations (more than two per year) despite high-dose inhaled corticosteroids (ICS 1000 μg
fluticasone propionate/day or equivalent dose).
• Smokers and ex-smokers with severe asthma (SAs/ex): this group was defined as for the SAn
group except that they were either current smokers or ex-smokers with at least five pack-
years smoking history.
In order to deepen potential effect of current smoking, we further divided all the severe
asthma U-BIOPRED subjects into three subgroups by smoking status: Current smokers with
Severe Asthma (CSA); Ex-smokers with Severe Asthma (ESA); Non-smokers with Severe
Asthma (NSA).
All enrolled subjects underwent a baseline visit during which clinical data, and urine and
sputum samples were collected. An optional broncoscopy visit was carried out only in special-
ist centres. Clinical and omic data of severe asthma cohorts were downloaded on June 2016
from U-BIOPRED database (tranSMART system) [15]. We obtained urine 8-iso-PGF2α data
from 411 severe asthma subjects, and IS, BB, BBr transcriptomincs data from 84, 53, 67 severe
asthma subjects, respectively. There is a good overlap, in term of patient coverage between
BB, BBr and urine, and between sputum and urine. In contrast, there is little overlap between
patients who had IS and BB/BBr.
The study protocol was approved by the Ethics Review Board of the Academic Medical
Centre of the University of Amsterdam (The Netherlands) and subsequently by the Ethics
Boards of all other clinical centres in the study (see S1 File. Material and Methods). The study
Oxidative stress in Severe Asthma U-BIOPRED cohorts
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adhered to the standards set by International Conference on Harmonisation and Good Clini-
cal Practice. All participants signed a written informed consent.
8-iso-PGF2α assessment
8-iso-PGF2α was extracted from spot urine samples using solid phase extraction (SPE) and
quantified via liquid chromatography coupled to mass spectrometry (LC-MS/MS) using an
Acquity UPLC coupled to a Xevo TQ-S mass spectrometer (Waters, Milford, MA). Optimal
extraction volumes for SPE were calculated using individual UV absorbance (λ = 300 nm)
measurements to minimize matrix effects, and levels of 8-iso-PGF2α were normalized to uri-
nary creatinine concentrations as previously published [16].
Microarray assessment
RNA from RNAlater-preserved IS cell pellet, BB, and BBr samples were extracted using Qiagen
miRNeasy kit and amplified with Nugen ovation pico WTA kit (NuGen Technologies; San Car-
los, CA). The cDNA was analysed using the Affymetrix HG-U133+PM microarray platform
(Affymetrix, Santa Clara, CA). The primary raw data images (DAT files) were processed into
numerical CEL files. CEL files were normalized, assessed for quality control to exclude technical
outliers, and re-normalized using the robust multi-array (RMA) method. Batch effects from
RNA processing sets were observed for the sputum and BBr datasets, with the batch effect
adjusted in the data matrices using linear modeling of batch (as a random factor) and cohort in
the ComBat R programme. For the sputum dataset, 3 subjects had duplicate samples, of which
the mean of the log2 intensities, after RNA processing set batch adjustment, were used in
the final analysis dataset. The limit of reliable quantification (LOD) was established from the
inflection point of maximum variance with decreasing signal in a standard deviation vs.
mean intensity plot across all probe sets and nonspecific probesets distribution. The cut-offs
(number of probe sets included) were 5.5 (23496), 5.0 (18697), and 4.75 (21363) for sputum,
BB, and BBr, respectively. The probe sets used in this study were as follow: NOX2 (203922_
PM_s_at, 203923_PM_s_at, 217431_PM_x_at, 233538_PM_s_at); NOS1 (1560974_PM_s_at,
207309_PM_at, 207310_PM_s_at, 231916_PM_at, 239132_PM_at, 240911_PM_at); NOS2
(210037_PM_s_at); NOS3 (205581_PM_s_at); SOD1 (200642_PM_at); SOD2 (215078_PM_at,
215223_PM_s_at, 216841_PM_s_at, 221477_PM_s_at); SOD3 (205236_PM_x_at); CAT
(201432_PM_at, 211922_PM_s_at, 215573_PM_at); GPX1 (200736_PM_s_at). Usually, probes
are selected to represent genes and are designed to match particular mRNA transcripts, often
based on deposited NCBI sequences. However, those sequences might be incorrect, partially
inaccurate or incomplete due to different problems. Moreover a gene can have multiple splice
variants [17]. Thus, multiple probe sets assigned to a common gene were studied separately in
order to keep an unbiased reporting of all relevant probe sets. Public repository for microarray
data are published in GEO website: GSE76262 (IS data); GSE76225 (BB data); GSE76226 (BBr
data).
Statistical analysis
Categorical data were summarized by counts and percentages; continuously distributed data
exhibiting approximate symmetry of distribution were summarized using the mean (standard
error; SE); continuously distributed data exhibiting skewness were summarized using the
median (inter-quartile range; IQR). The latter all exhibited positive skewness and were log-
transformed prior to parametric association testing. P-values were calculated by applying
ANOVA to a generalised linear model. ANOVA was performed using logistic regression with
adjustment for age and gender. All analyses were considered significant with a p-value of less
Oxidative stress in Severe Asthma U-BIOPRED cohorts
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than 5%. Acknowledging the modest sample size of the current exploratory study, adjustments
for multiple-testing were not applied. Moreover, a negative result should be considered incon-
clusive. In order to characterise further some of the observed associations, rank correlation
was assessed by calculation of Kendall’s Tau. A p-value was calculated in a test of the null
hypothesis of zero correlation. Analyses of clinical and inflammatory data were performed
using R version 2.15.2 (R Core Team, 2012).
Results
Clinical parameters
The clinical and inflammatory characteristics of all U-BIOPRED patients have been previously
described [13]. Here, we compared the main clinical data between SAn and SAs/ex groups, as
well as between all SA subjects when stratified by smoking status. i.e., CSA, ESA and NSA
groups. These results are reported in S1–S4 Tables and Tables 1–4, respectively, for each sub-
ject subset (urine-8-iso-PGF2α; IS-transcriptomics; BB-transcriptomics; BBr-transcriptomics).
In brief, the onset of asthma occurred later in SAs/ex than in SAn for urine-8-iso-PGF2α (p<
0.001) and IS-transcriptimics (p< 0.031) subsets, although the subjects had a similar degree of
airway obstruction (spirometry data). An older age at diagnosis was also observed in the CSA
and/or ESA than NSA, but only in the urine-8-iso-PGF2α subset (p< 0.001). Gastro-esophageal
reflux disease (GERD) was increased in SAs/ex compared to SAn in the urine-8-iso-PGF2α
subset (p = 0.006), and this trend was also observed in the other subsets (p> 0.05). GERD was
also increased in CSA for the urine-8-iso-PGF2α subset (p = 0.009) compared to ESA and
NSA. FEV1/FVC ratio was decreased in CSA than ESA and NSA with significant p-value in the
urine-8-iso-PGF2α subset (p = 0.033). FeNO levels were significantly lower in SAs/ex than SAn
for those subjects for whom BB and BBr transcriptomic data was available, but this was not
seen across all subsets. However, when compared SA smoking subgroups we observed that
FeNO levels were significantly lower in CSA than ESA and NSA for all subject subsets. Regular
OCS use was increased in ESA than CSA and NSA with significant p value in the urine-8-iso-
PGF2α (p = 0.002) and BBr transcriptomics (p = 0.009) subsets.
Lipid peroxidation
We analysed 8-iso-PGF2α, a specific biomarker of lipid peroxidation, in spot urine samples.
The median (IQR) concentration of 8-iso-PGF2α was significantly increased in the urine of
SAs/ex compared to SAn, 31.7 (24.5–44.7) vs. 26.6 (19.6–36.6) ng/mmol creatinine respectively
(FC = 1.19; p< 0.001) (Fig 1A), Furthermore, we assessed levels of 8-iso-PGF2α taking into
consideration smoking status within the two combined SA cohorts (SAn+SAs/ex). A signifi-
cant difference was observed between the smoking subgroups (p = 0.004) with increased
median (IQR) concentration of urinary 8-iso-PGF2α in CSA, 34.25 (24.4–47.7), vs ESA, 29.4
(22.3–40.5), and NSA, 26.5 (19.6–16.6) ng/mmol creatinine (Fig 1B).
mRNA expression of pro-/anti-oxidant enzymes
All the results about mRNA expression of pro-/antioxidant enzymes are reported in Table 5.
Sputum mRNA levels of the pro-oxidant enzymes NOX2 and NOS3 were examined. The
mRNA levels of NOX2 were increased in SAs/ex compared to SAn. In particular the probe
sets 203922_PM_s_at (FC = 1.05 p = 0.006), 203923_PM_s_at (FC = 1.06; p = 0.003),
233538_PM_s_at (FC = 1.06; p = 0.014) were over-expressed in SAs/ex. The NOX2 probe set
217431_PM_x_at is less abundant than the other probe sets, and was not significantly different
between SAn and SAs/ex (FC = 1.00; p = 0.950). The expression of NOS3 mRNA in IS was
Oxidative stress in Severe Asthma U-BIOPRED cohorts
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similar between SAs/ex and SAn, while the levels of NOS1, NOS2 probe sets, together with
the anti-oxidative SOD3, were below the limit of detection (LOD). CAT mRNA levels were
over-expressed in IS of SAs/ex compared to SAn for the probe set 201432_PM_at (FC = 1.07;
p = 0.028), but the probe set 211922_PM_s_at did not show a significant difference (p = 0.359).
By contrast, IS mRNA expression of SOD1, SOD2, SOD3 and GPX1 were not statistically dif-
ferent between SAn and SAs/ex.
All of the pro-oxidant enzymes were excluded in BB analyses because their expression levels
were below the LOD. The expression of all antioxidant enzymes in BB was similar among SAn
and SAs/ex.
NOS2 mRNA levels were significantly decreased in BBr of SAs/ex compared to SAn (FC =
-1.10; p = 0.029). BBr NOS3 mRNA expression was similar between SAn and SAs/ex (FC =
-1.01; p = 0.310). In addition, the mRNA expression levels of anti-oxidant enzymes in BBr
were similar among the two study groups. NOX2, NOS1 and SOD3 were excluded from the
analysis in BBr subset because their mRNA expression levels were below the LOD.
When stratification was made based on smoking status a low number of subjects were avail-
able for which oxidant/anti-oxidant enzyme mRNA expression data could be used with suffi-
cient statistical power and therefore this analysis was not performed.
Correlation analysis
Two NOX2 probe sets in sputum correlated significantly with macrophage numbers (203922_
PM_s_at Kendall’s Tau = 0.49, p< 0.001; 203923_PM_s_at Kendall’s Tau = 0.45 p< 0.001) and
Table 1. Clinical and inflammatory characteristics of severe asthma non-, ex-, and current-smokers present in the Urinary 8-iso-PGF2α subset.
NSA ESA CSA p-value
Subjects n. 260 112 42
Age (yr) 52 (42–61) [n = 260] 56 (50–62) [n = 112] 52.5 (46–58) [n = 42] <0.001§
Female 171/260 (65.77%) 62/112 (55.36%) 24/42 (57.14%) 0.058
Age at Diagnosis(yr) 19.5 (7–37) [n = 252] 37.5 (20–48) [n = 110] 26.5 (7–42) [n = 42] <0.001§
Exacerbations (History) 2 (1–3) [n = 259] 2 (1–3) [n = 112] 1 (0–4) [n = 42] 0.488
Pack Years NA (NA-NA) [0] 8.43 (3–18) [n = 112] 20.15 (14–28) [n = 42] <0.001§
Allergic Rhinitis Diagnosed 136/229 (59.39%) 46/106 (43.4%) 22/36 (61.11%) 0.007§
Nasal Polyps Diagnosed 79/241 (32.78%) 46/109 (42.2%) 9/36 (25%) 0.089
GERD Diagnosed 108/240 (45%) 64/106 (60.38%) 23/35 (65.71%) 0.009§
FEV1% pred 67.74 (51–85) [n = 257] 65.67 (52–82) [n = 112] 64.48 (50–75) [n = 42] 0.561
FVC % pred 86.97 (73–101) [n = 257] 90.25 (77–102) [n = 112] 86.88 (77–97) [n = 42] 0.104
FEV1/FVC ratio 0.65± 0.01 [n = 257] 0.61± 0.01 [n = 112] 0.6± 0.02 [n = 42] 0.033§
Exhaled NO 27 (16–48) [n = 240] 25 (15–48) [n = 106] 16 (10–31) [n = 41] <0.001§
Sputum Eosinophils 15 (2–84) [n = 105] 20 (2–85) [n = 55] 13 (4–36) [n = 21] 0.585
Sputum Neutrophils 276 (160–400) [n = 105] 281 (200–382) [n = 55] 292 (203–343) [n = 21] 0.28
Sputum Eosinophils (%) 2.86 (0–18) [n = 105] 3.81 (1–17) [n = 55] 2.47 (1–7) [n = 21] 0.572
Sputum Neutrophils (%) 53.98 (32–75) [n = 105] 55.1 (44–72) [n = 55] 55.94 (35–64) [n = 21] 0.226
Mean ACQ with ACQ7 2.71 (2–4) [n = 236] 2.43 (2–3) [n = 95] 2.79 (2–3) [n = 38] 0.135
Regular ICS or ICS/LABA Use 259/260 (99.62%) 112/112 (100%) 42/42 (100%) 0.997
Regular Oral Corticosteroids 117/250 (46.8%) 53/103 (51.46%) 8/40 (20%) 0.002§
Data are presented as mean±SE [n], median (interquartile range) [n] or n/N (%), unless otherwise stated. ACQ: Asthma Control Questionnaire; CSA: current smokers
with severe atshma; ESA: ex-smokers with severe asthma; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GERD: gastro-esophageal reflux
disease; ICS: inhaled corticosteroids; LABA: long-acting β2-agonist; NSA: non-smokers with severe asthma.
§ significant p value
https://doi.org/10.1371/journal.pone.0203874.t001
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percentages (203922_PM_s_at Kendall’s Tau = 0.48, p< 0.001; 203923_PM_s_at Kendall’s
Tau = 0.43 p< 0.001). Inversely correlations were observed between three NOX2 probe sets
and eosinophil numbers (203922_PM_s_at Kendall’s Tau = -0.19, p = 0.01; 203923_PM_s_at
Kendall’s Tau = -0.24, p = 0.002; 233538_PM_s_at Kendall’s Tau = -0.22, p = 0.004), and per-
centages (203922_PM_s_at Kendall’s Tau = -0.20, p = 0.008; 203923_PM_s_at Kendall’s
Tau = -0.24, p = 0.001; 233538_PM_s_at Kendall’s Tau = -0.22, p = 0.004). One NOX2
probe set in sputum inversely correlated with neutrophil numbers (203922_PM_s_at
Kendall’s Tau = -0.18, p = 0.014), while two NOX2 probe sets inversely correlated with neutro-
phil percentages (203922_PM_s_at Kendall’s Tau = -0.18, p = 0.014; 203923_PM_s_at Ken-
dall’s Tau = -0.15, p = 0.038) However, there was no correlation between NOX2 mRNA in
sputum and 8-iso-PGF2α in urine (all the four probe sets had p> 0.10). Moreover, a strong
correlation between NOS2 in BBr and FeNO was observed with a Kendall’s Tau = 0.535
(p< 0.001) (Fig 2). The correlation analysis between NOS2 in BBr and FeNO was also per-
formed for each smoking status group (i.e., NSA, ESA, CSA): where we observed a significant
correlation in 36 NSA (Kendall’s Tau = 0.551; p< 0.001); in 20 ESA (Kendall’s Tau = 0.394;
p = 0.085); the number of CSA subjects was six and therefore correlation analysis was consid-
ered not appropriate.
Discussion
We used data from the U-BIOPRED severe asthma cohorts to assess the effect of cigarette
smoke on oxidative stress markers in severe asthma subjects with a significat smoking history.
Table 2. Clinical and inflammatory characteristics of severe asthma non-, ex-, and current-smokers present in the induced sputum-transcriptomic subset.
NSA ESA CSA p-value
Subjects n. 47 29 8
Age (yr) 53 (44–60) [n = 47] 56 (52–62) [n = 29] 46.5 (45–55) [n = 8] 0.073
Female 28/47 (59.57%) 17/29 (58.62%) 4/8 (50%) 0.613
Age at Diagnosis (yr) 17 (5–38) [n = 47] 38.5 (26–49) [n = 28] 24 (7–33) [n = 8] 0.563
Exacerbations (History) 2 (1–3) [n = 47] 2 (1–3) [n = 29] 1.5 (1–4) [n = 8] 0.593
Pack Years NA (NA_NA) [n = 0] 7 (2–15) [n = 29] 18.25 (13–23) [n = 8] 0.034§
Allergic Rhinitis Diagnosed 19/39 (48.72%) 10/28 (35.71%) 2/7 (28.57%) 0.291
Nasal Polyps Diagnosed 16/45 (35.56%) 12/29 (41.38%) 2/7 (28.57%) 0.614
GERD Diagnosed 17/45 (37.78%) 17/28 (60.71%) 4/6 (66.67%) 0.059
FEV1% pred 59.93 (45–74) [n = 47] 63.93 (55–75) [n = 29] 73.49 (70–76) [n = 8] 0.082
FVC % pred 85.29 (73–98) [n = 47] 93.66 (81–108) [n = 29] 99.07 (86–105) [n = 8] 0.018§
FEV1/FVC ratio 0.57± 0.02 [n = 47] 0.58± 0.02 [n = 29] 0.61± 0.03 [n = 8] 0.416
Exhaled NO 26 (19–49) [n = 45] 28.5 (15–53) [n = 28] 10.75 (8–18) [n = 8] 0.007§
Sputum Eosinophils 15 (2–69) [n = 47] 29 (2–89) [n = 29] 17 (2–41) [n = 8] 0.505
Sputum Neutrophils 327 (192–434) [n = 47] 281 (235–381) [n = 29] 271 (234–328) [n = 8] 0.414
Sputum Eosinophils (%) 2.86 (0–14) [n = 47] 5.66 (0–19) [n = 29] 3.23 (0–8) [n = 8] 0.575
Sputum Neutrophils (%) 68.22 (35–84) [n = 47] 55.15 (47–74) [n = 29] 53.55 (44–64) [n = 8] 0.369
Mean ACQ with ACQ7 2.71 (1–4) [n = 44] 2.14 (2–3) [n = 26] 2.29 (2–4) [n = 7] 0.609
Regular ICS or ICS/LABA Use 47/47 (100%) 29/29 (100%) 8/8 (100%) 1
Regular Oral Corticosteroids 19/46 (41.3%) 16/27 (59.26%) 3/7 (42.86%) 0.141
Data are presented as mean±SE [n], median (interquartile range) [n] or n/N (%), unless otherwise stated. ACQ: Asthma Control Questionnaire; CSA: current smokers
with severe asthma; ESA: ex-smokers with severe asthma; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GERD: gastro-esophageal reflux
disease; ICS: inhaled corticosteroids; LABA: long-acting β2-agonist; NSA: non-smokers with severe asthm.
§ significant p value
https://doi.org/10.1371/journal.pone.0203874.t002
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We found an increased systemic oxidative stress in SAs/ex, and in particular among severe
asthma current smokers, who exhibited the highest concentration of urinary 8-iso-PGF2α. In
sputum, NOX2 mRNA expression was increased in SAs/ex compared to SAn, while NOS2
mRNA expression was decresead in bronchial brushing of SAs/ex. Moreover, levels of FeNO
were decresed in severe asthma current smokers, and was correlated with NOS2 mRNA
expression in bronchial brushing.
Tobacco smoke is one of the major environmental sources of oxidative stress and can
lead to greater lipid peroxidation. It has been shown that 8-iso-PGF2α levels are elevated with
asthma severity [11] and further enhanced during acute exacerbations [18] and allergen chal-
lenge in asthmatics [11]. Our data provide additional support for the findings in other studies,
showing the ability of cigarette smoke to increase isoprostane levels, by the increased level of
urinary 8-iso-PGF2α in SAs/ex, and in particular, in the current smokers subgroup [19,20].
However, our data extended the previous findings showing the incresase of this oxidative stress
biomarker in smokers with severe asthma. F2 isoprostanes have a potent smooth muscle and
vascular constrictive action which increases airway hyperresponsiveness and obstruction, and
induces plasma exudation and inflammation [21]. Thus, the increased formation of 8-iso-
PGF2α in smoking asthmatics, as induced by cigarette smoke, may enhance disease progres-
sion and asthma symptoms.
The NOX2 isoform is primarily present in macrophages, neutrophils and eosinophils and
is most highly abundant in IS. NOX2 activity is normally required for phagocyte respiratory
burst and regulation of cell signaling [22,23]. Furthermore, the enzyme NOX2 is activated by
Table 3. Clinical and inflammatory characteristics of severe asthma non-, ex-, and current-smokers present in the bronchial biopsy-transcriptomic subset.
NSA ESA CSA p-value
Subjects n. 34 12 7
Age (yr) 51.5 (43–60) [n = 34] 54.5 (43–62) [n = 12] 52 (46–55) [n = 7] 0.779
Female 21/34 (61.76%) 2/12 (16.67%) 5/7 (71.43%) 0.014§
Age at Diagnosis(yr) 10 (2–40) [n = 33] 5.5 (2–38) [n = 12] 33 (18–44) [n = 7] 0.429
Exacerbations (History) 2 (0–4) [n = 33] 2.5 (1–3) [n = 12] 4 (2–5) [n = 7] 0.078
Pack Years NA (NA_NA) [n = 0] 5.25 (2–25) [n = 12] 20.5 (17–24) [n = 7] 0.067
Allergic Rhinitis Diagnosed 19/31 (61.29%) 6/12 (50%) 2/7 (28.57%) 0.132
Nasal Polyps Diagnosed 10/32 (31.25%) 8/12 (66.67%) 1/7 (14.29%) 0.04§
GERD Diagnosed 16/33 (48.48%) 9/12 (75%) 4/6 (66.67%) 0.123
FEV1% pred 74.17 (54–89) [n = 34] 69.35 (57–77) [n = 12] 68.7 (55–72) [n = 7] 0.405
FVC % pred 89.19 (78–103) [n = 34] 87.15 (75–97) [n = 12] 93.8 (91–100) [n = 7] 0.443
FEV1/FVC ratio 0.67± 0.02 [n = 34] 0.65± 0.03 [n = 12] 0.58± 0.03 [n = 7] 0.081
Exhaled NO 30 (20–46) [n = 29] 23 (20–50) [n = 12] 8 (7–23) [n = 7] 0.005§
Sputum Eosinophils 20 (6–84) [n = 18] 2.5 (2–9) [n = 4] 6.5 (2–14) [n = 4] 0.176
Sputum Neutrophils 254 (215–319) [n = 18] 364 (216–470) [n = 4] 260 (154–347) [n = 4] 0.105
Sputum Eosinophils (%) 3.62 (1–16) [n = 18] 0.53 (0–2) [n = 4] 1.3 (0–3) [n = 4] 0.134
Sputum Neutrophils (%) 51.47 (41–56) [n = 18] 66.66 (40–88) [n = 4] 49.23 (27–69) [n = 4] 0.119
Mean ACQ with ACQ7 2 (1–3) [n = 29] 2.29 (1–4) [n = 10] 3 (2–4) [n = 5] 0.092
Regular ICS or ICS/LABA Use 34/34 (100%) 12/12 (100%) 7/7 (100%) 1
Regular Oral Corticosteroids 14/32 (43.75%) 6/11 (54.55%) 2/7 (28.57%) 0.465
Data are presented as mean±SE [n], median (interquartile range) [n] or n/N (%), unless otherwise stated. ACQ: Asthma Control Questionnaire; CSA: current smokers
with severe asthma; ESA: ex-smokers with severe asthma; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GERD: gastro-esophageal reflux
disease; ICS: inhaled corticosteroids; LABA: long-acting β2-agonist; NSA: non-smokers with severe asthm.
§ significant p value
https://doi.org/10.1371/journal.pone.0203874.t003
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cigarette smoke through the phosphorylation of c-Src [24], a tyrosine kinase protein, leading
to a higher production of ROS [24,25]. In our study, NOX2 mRNA is over-expressed in spu-
tum of SAs/ex compared to SAn, supporting the hypothesis that exposure to smoke in asth-
matic subjects is able to amplify NOX2 mRNA expression with a consequent elevation of O2•-
Table 4. Clinical and inflammatory characteristics of severe asthma non-, ex-, and current-smokers present in the bronchial brushing-transcriptomic subset.
NSA ESA CSA p-value
Subjects n. 40 21 6
Age (yr) 51 (40–59) [n = 40] 53 (46–62) [n = 21] 53.5 (44–55) [n = 6] 0.413
Female 22/40 (55%) 6/21 (28.57%) 4/6 (66.67%) 0.053
Age at Diagnosis(yr) 15.5 (5–42) [n = 38] 24 (5–39) [n = 21] 31.5 (13–40) [n = 6] 0.563
Exacerbations (History) 2 (1–4) [n = 39] 2 (1–3) [n = 21] 3.5 (2–5) [n = 6] 0.283
Pack Years NA (NA_NA) [n = 0] 5.5 (3–22) [n = 21] 19.5 (17–23) [n = 6] 0.122
Allergic Rhinitis Diagnosed 21/35 (60%) 11/21 (52.38%) 1/6 (16.67%) 0.079
Nasal Polyps Diagnosed 12/35 (34.29%) 12/20 (60%) 1/6 (16.67%) 0.068
GERD Diagnosed 21/37 (56.76%) 13/21 (61.9%) 4/5 (80%) 0.339
FEV1% pred 79.33 (57–93) [n = 40] 65.66 (55–74) [n = 21] 69.48 (61–73) [n = 6] 0.072
FVC % pred 94.27 (77–104) [n = 40] 85.78 (76–94) [n = 21] 95.53 (93–101) [n = 6] 0.188
FEV1/FVC ratio 0.69± 0.02 [n = 40] 0.62± 0.02 [n = 21] 0.59± 0.04 [n = 6] 0.054
Exhaled NO 31.25 (19–54) [n = 36] 23.5 (20–63) [n = 20] 7.75 (7–13) [n = 6] 0.001§
Sputum Eosinophils 20 (2–94) [n = 16] 3 (2–26) [n = 9] 3 (2–6) [n = 3] 0.216
Sputum Neutrophils 235 (208–312) [n = 16] 263 (183–454) [n = 9] 317 (260–378) [n = 3] 0.556
Sputum Eosinophils (%) 3.62 (0–18) [n = 16] 0.71 (0–5) [n = 9] 0.6 (0–1) [n = 3] 0.183
Sputum Neutrophils (%) 49.23 (39–60) [n = 16] 46.88 (32–86) [n = 9] 63.4 (49–75) [n = 3] 0.543
Mean ACQ with ACQ7 2 (1–3) [n = 31] 2.29 (1–3) [n = 16] 3 (2–4) [n = 5] 0.081
Regular ICS or ICS/LABA Use 40/40 (100%) 21/21 (100%) 6/6 (100%) 1
Regular Oral Corticosteroids 13/37 (35.14%) 14/19 (73.68%) 1/6 (16.67%) 0.009§
Data are presented as mean±SE [n], median (interquartile range) [n] or n/N (%), unless otherwise stated. ACQ: Asthma Control Questionnaire; CSA: current smokers
with severe asthma; ESA: ex-smokers with severe asthma; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GERD: gastro-esophageal reflux
disease; ICS: inhaled corticosteroids; LABA: long-acting β2-agonist; NSA: non-smokers with severe asthm.
§ significant p value
https://doi.org/10.1371/journal.pone.0203874.t004
Fig 1. (A) Comparison of 8-iso-PGF2α in urine between SAn and SAs/ex. (B) Comparison of urinary 8-iso-PGF2α between severe asthma smoking subgroups.
CSA: current smokers with severe asthma; ESA: ex-smokers with severe asthma; NSA: non smokers with severe asthma; SAn: Severe Asthma non smokers; SAs/ex:
Severe Asthma smokers/ex-smokers.
https://doi.org/10.1371/journal.pone.0203874.g001
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production. However, we could not establish a significant correlation between NOX2 over-
expression in IS and urinary 8-iso-PGF2α. Certainly, NOX2 is just one of the several factors
contributing to the increase of oxidative stress. The positive correlation of NOX2 mRNA
with macrophages in sputum and the inverse relationship with phagocytes may highlight the
importance of distinct cellular phenotypes in regulating the inflammatory process in severe
asthmatics who smoke [26,27]. This area deserves further investigation.
NOS enzymes are important pro-oxidants producing NO, an endogenous regulator
involved in homeostatic and immunological functions with a role in asthma pathogenesis
[9]. We observed no differences in mRNA expression of constitutive NOS3 between SAn and
Table 5. Comparison of pro-/anti-oxidant enzyme mRNA expression in induced sputum, bronchial biopsies and bronchial brushings between severe asthma
cohorts.
Gene symbol Probe set ID SAn mean SAs/ex mean Fold Change p value
Induced Sputum (SAn n = 61; SAs/ex n = 23): LOD = 5.5 log2 intensity
NOX2 203922_PM_s_at 9.89 10.35 1.05 0.006
203923_PM_s_at 9.03 9.59 1.06 0.003
217431_PM_x_at 5.96 5.97 1 0.950
233538_PM_s_at 6.57 6.96 1.06 0.014
NOS3 205581_PM_s_at 6.32 6.19 -1.02 0.115
SOD1 200642_PM_at 8.37 8.69 1.04 0.094
SOD2 215078_PM_at 9.93 9.62 -1.03 0.225
215223_PM_s_at 11.65 11.46 -1.02 0.303
216841_PM_s_at 11.40 11.20 -1.02 0.098
221477_PM_s_at 11.26 10.99 -1.02 0.121
CAT 201432_PM_at 8.41 9.01 1.07 0.028
211922_PM_s_at 7.81 7.97 1.02 0.359
GPX1 200736_PM_s_at 9.57 9.74 1.02 0.385
Bronchial Biopsy (SAn n = 40; SAs/ex n = 13): LOD = 5 log2 intensity
SOD1 200642_PM_at 8.36 8.30 -1.01 0.253
SOD2 215223_PM_s_at 7.00 7.03 1.00 0.667
216841_PM_s_at 6.35 6.10 -1.04 0.075
221477_PM_s_at 6.28 6.11 -1.03 0.148
SOD3 205236_PM_x_at 6.77 7.07 1.04 0.161
CAT 201432_PM_at 6.84 6.89 1.01 0.941
211922_PM_s_at 5.73 5.68 -1.01 0.558
GPX1 200736_PM_s_at 7.04 7.19 1.02 0.437
Bronchial Brushing (SAn n = 49; SAs/ex n = 18): LOD = 4.5 log2 intensity
NOS2 210037_PM_s_at 5.36 4.87 -1.10 0.029
NOS3 205581_PM_s_at 4.97 4.88 -1.02 0.310
SOD1 200642_PM_at 9.03 8.99 -1.00 0.802
SOD2 215223_PM_s_at 7.58 7.25 -1.05 0.176
216841_PM_s_at 6.90 6.56 -1.05 0.165
221477_PM_s_at 6.84 6.60 -1.04 0.206
CAT 201432_PM_at 7.47 7.39 -1.01 0.620
211922_PM_s_at 6.20 6.24 1.01 0.681
GPX1 200736_PM_s_at 7.56 7.58 1.00 0.960
P-values were calculated by applying ANOVA with adjustment for age and gender. LOD: limit of detection; NOX2: NADPH oxidase 2; NOS2/3: nitric oxide synthase 2/
3; SOD1/2/3: superoxide dismutase 1/2/3; CAT: catalase; GPX1: glutathione peroxidase 1; SAn: severe asthma non smokers; SAs/ex: severe asthma smokers/ex-smokers.
https://doi.org/10.1371/journal.pone.0203874.t005
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SAs/ex, which suggests that cigarette smoke has a weak relation to NOS3 expression, if any.
NOS2 is the inducible isoform (iNOS), which produces high levels of NO and its activity per-
sists for many days after induction [28,29], leading to cell death and tissue damage [28]. This
enzyme is mainly expressed in lung epithelium [29], so it is mainly detectable in BBr. NOS2
mRNA expression is induced by pro-inflammatory cytokines [9,30], and is increased in
asthma in proportion to the severity of the disease [31], and in particular by allergen provoca-
tion [32]. In this study, levels of NOS2 mRNA from BBr of SAs/ex was lower than that of SAn.
Furthermore, we demonstrated a strong correlation between FeNO levels and BBr NOS2
mRNA expression in SA cohorts, as also have been reported previously [33]. Another study
has shown that NO generated by NOS2 is able to attenuate its own expression through the
negative regulation of NF-κB [34]. Therefore, we hypothesise that active exposure to cigarette
smoke can lead to inhibition of NOS2 mRNA expression in a negative feedback manner.
Fig 2. Scatter plot of the relationship between NOS2 expression in bronchial brushing and FeNO. NOS2 expression in bronchial brushing
were strongly correlated to FeNO. Kendall’s Tau = 0.535, p< 0.001, (n = 62). FeNO (ppb) were log2-transformed. SAn: Severe Asthma non
smokers; SAs/ex: Severe Asthma smokers/ex-smokers.
https://doi.org/10.1371/journal.pone.0203874.g002
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Evidence exists of lower FeNO levels in asthmatic smokers [35,36], which has also been
shown in this U-BIOPRED adult SAs/ex cohort [13], indicating a possible effect of active
smoking on levels of exhaled NO. Further analysis of FeNO, in relation to the cigarette smok-
ing status of patients (current-, ex- and never-smokers), showed decreased FeNO levels in cur-
rent smokers confirming the effect of active smoking on exhaled NO [36]. Despite the fact that
superoxide concentration is known to be high in cigarette smoke, and thereby it can enhance
the reduction of FeNO by reacting with available NO, we demonstrated a significant correla-
tion between NOS2 in bronchial brushings and FeNO in severe asthmatic subjects. Moreover,
the peroxynitrite product of this reaction is a very strong oxidant species [8–10]. Thus, knowl-
edge of current smoking status is important when using FeNO measurements in assessing
asthma control and severity.
The anti-oxidant enzymes—SODs, CAT and GPX1 —catalyze reactions to neutralize oxida-
tive toxic intermediates. SODs are the primary enzymes able to dismantle superoxide anion
to form H2O2. Whereas, CAT and GPX1 are key antioxidant enzymes for the degradation of
reactive H2O2 to H2O and O2 [10]. We observed no significant differences in SOD1, SOD2
and SOD3 mRNA expression, as well as for CAT and GPX1 mRNA expression, in airways of
SAn and SAs/ex. To our knowledge, there are no reports concerning antioxidant enzyme sta-
tus in severe asthma smokers. However, some evidences relating to expression of SODs, CAT
and GPX1 enzymes in relation to asthma or cigarette smoke were found in the literature. Sev-
eral studies reported that SOD1 has low activity and expression in asthmatic airways [10,37]
and, in addiction, SOD2 was found to be inactivated and down regulated in asthmatic patients
[37–39]. Furthermore, the expression of SOD3 seems to be decreased in vitro by TNF-α,
TGF-β and IL1-α, while it is enhanced by IFN-γ [10,40]. Cigarette smoke enhanced the expres-
sion [41] and activity [42] of SODs in rat airways. Conversely, the levels of SOD were found
increased in blood and saliva of subjects who smoke [43], and prolonged cigarette smoke expo-
sure was found to increase the mRNA level of SOD2 in human bronchial epithelial cells [44].
Therefore, it is conceivable that whilst SOD mRNA expression is decreased in SA, smoking
enhances SOD mRNA expression, resulting in a balance between the two actions and overall
no difference between SAn and SAs/ex. Catalase (protein and mRNA levels) was previously
reported as decreased in the bronchiolar epithelium of smokers with COPD [45]. Further-
more, the activity of CAT and GPX was previously found reduced in asthmatic patients [10].
Further studies are required to determine whether the decreased expression reported by Bet-
suyaku et al. [45] was a result of smoking or of COPD.
Limitations of the study
Due to the explorative nature of this study, there are several limitations. One limitation is the
absence of a healthy smoker and a healthy non-smokers control groups, which do not allow us
to establish for sure the influence of cigarette smoking and/or severe asthma. Moreover, the
measurement of whole body excretion of 8-iso-PGF2α in urine cannot determine the source
(airways or systemic source). Given that the patients included in this study have the same
degree of asthma severity it is however likely that the observed changes are predominantly due
to smoking.
Few patients provided samples from each compartment within the U-BIOPRED study. Par-
ticularly, the number of SAs/ex samples is low for the sputum, BB and BBr transcriptomics set,
thus we cannot didived SAs/ex group into current and ex-smokers for the mRNA expression
analysis.
We evaluated the mRNA expression of pro-/anti-oxidant enzymes, but the mRNA levels
do not necessarily correlate with the activity of the corresponding enzymes or their products’
Oxidative stress in Severe Asthma U-BIOPRED cohorts
PLOS ONE | https://doi.org/10.1371/journal.pone.0203874 September 21, 2018 12 / 16
concentration. Moreover, mRNA-expression of several enzymes could not be accurately
assessed due to their low expression levels on the microarray. Although we report significant
differences in oxidant gene expression of SAs/ex, the changes are small and other mechanisms
driving asthma severity in these patients may be present. Independent replications of these
findings are warranted.
Conclusions
In conclusion, our results indicate that severe asthmatics who smoke have evidence for
increased systemic oxidative stress. The increased mRNA expression of NOX2 in the airway
lumen could contribute to this phenomenon. However, this is the first study in severe
asthma showing a clear relationship between cigarette smoking and reduced NOS2 expres-
sion together with lower levels of FeNO. Future studies are needed to investigate this com-
plex mechanism in the framework of smoking related to severe asthma.
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